Fidson Healthcare Plc recorded a pre-tax profit of N14.96 billion for the 2025 financial year, a 94% rise from the N7.7 billion achieved in 2024. The result comes from the company's audited financial statement for the period ending December 31, 2025, which reflects significant revenue growth and tighter control over costs. Despite rising operational expenses, the pharmaceutical firm maintained strong earnings momentum across its product lines. Revenue performance was driven by increased market share and expanded distribution networks.
The board has approved a dividend payout of N3.6 billion to shareholders for the 2025 fiscal year. This decision aligns with the company's policy of rewarding investors while reinvesting in production capacity. Fidson Healthcare continues to focus on local manufacturing and product innovation as key growth drivers. The company's financial statements were audited and confirmed by independent accountants.
A 94% jump in pre-tax profit for Fidson Healthcare is rare in Nigeria's current economic climate, where inflation and forex volatility strain manufacturing. The N3.6 billion dividend signals confidence in sustained cash flow, which many listed firms can't match. This performance puts Fidson ahead of several peers in the domestic pharma space. For Nigerian investors, it suggests that some local companies can still deliver strong returns despite systemic challenges.
